{"nctId":"NCT04855760","briefTitle":"Safety of REL-1017 for Major Depressive Disorder","startDateStruct":{"date":"2021-04-01","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":627,"armGroups":[{"label":"REL-1017","type":"EXPERIMENTAL","interventionNames":["Drug: REL-1017"]}],"interventions":[{"name":"REL-1017","otherNames":["Esmethadone HCl"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults 18 to 65 years, inclusive.\n* Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for DSM-5 (SCID-5) for MDD.\n* Current major depressive episode.\n\nExclusion Criteria:\n\n* Any current and primary psychiatric disorder other than Major Depressive Disorder.\n* History of bipolar I and II disorder, psychosis, and/or mania.\n* Acute or chronic condition that, in the Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs)","description":"Subjects with at least one Treatment Emergent Adverse Events (TEAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 3","description":"Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 3.\n\nA negative change from baseline indicates shortening of the QTcF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.11","spread":"14.54"}]}]}]},{"type":"SECONDARY","title":"Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 6","description":"Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 6.\n\nA negative change from baseline indicates shortening of the QTcF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"15.26"}]}]}]},{"type":"SECONDARY","title":"Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 12","description":"Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 12.\n\nA negative change from baseline indicates shortening of the QTcF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"13.77"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Month 3","description":"Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3.\n\nA negative change from baseline indicates a reduction in Diastolic Blood Pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Month 12","description":"Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12.\n\nA negative change from baseline indicates a reduction in Diastolic Blood Pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Month 3","description":"Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3.\n\nA negative change from baseline indicates a reduction in Systolic Blood Pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Month 12","description":"Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12.\n\nA negative change from baseline indicates a reduction in Systolic Blood Pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"10.9"}]}]}]},{"type":"SECONDARY","title":"Change in Heart Rate From Baseline to Month 3","description":"Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 3.\n\nA negative change from baseline indicates a reduction in Heart Rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"9.2"}]}]}]},{"type":"SECONDARY","title":"Change in Heart Rate From Baseline to Month 12","description":"Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 12.\n\nA negative change from baseline indicates a reduction in Heart Rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"9.6"}]}]}]},{"type":"SECONDARY","title":"Change in Weight From Baseline to Month 3","description":"Overall Safety of REL-1017 as measured by Weight From Baseline to Month 3.\n\nA negative change from baseline indicates a reduction in Weight.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"4.45"}]}]}]},{"type":"SECONDARY","title":"Change in Weight From Baseline to Month 12","description":"Overall Safety of REL-1017 as measured by Weight From Baseline to Month 12.\n\nA negative change from baseline indicates a reduction in Weight.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"5.56"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in the MADRS10 Total Score From Baseline to Month 3","description":"Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression.\n\nA negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"10.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in the MADRS10 Total Score From Baseline to Month 12","description":"Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression.\n\nA negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.6","spread":"10.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":624},"commonTop":["Headache","COVID-19","Upper respiratory tract infections"]}}}